Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program
Watch Newron Pharmaceuticals' latest callNewron Pharmaceuticals (SIX Swiss: NWRN) Q4 2025 Earnings Call · Replay · Mar 24Read the transcript of Newron Pharmaceuticals (SIX Swiss: NWRN) Q4 2025 Earnings CallThe original release is unavailable here.
Newron Pharmaceuticals S.p.A. on 6ix
Earlier from Newron Pharmaceuticals
- Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia
- EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan
- Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent
- Newron to Host Investor and Partnering Meetings During the J.P. Morgan Healthcare Conference Week
- Newron Announces the US Initiation of Its ENIGMA-TRS 2 Phase III Global Clinical Study With Evenamide as an Add-On Therapy for Patients With Treatment-Resistant Schizophrenia (TRS)
Later from Newron Pharmaceuticals
- Newron announces nominations to its Board of Directors at upcoming Annual General Meeting
- Newron Pharmaceuticals S p A announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 Finance Contract
- Newron to Present at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
- Newron Pharmaceuticals S p A presents 2025 financial results and provides 2026 outlook
- Newron presents 2025 financial results and provides 2026 outlook
Follow Newron Pharmaceuticals into a list and get an email when it puts out news.
Follow Newron Pharmaceuticals